Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.
百诚医药
301096
Shenzhen Stock Exchange
Company Profile
The company focuses on the forefront of innovation. Through the construction of AI models with independent intellectual property rights, the applied research of biochips, and the establishment of organoid libraries, it explores and innovates new R & D models. Based on the above - mentioned technologies, the company conducts innovative R & D of drugs for respiratory system diseases, mental and neurological diseases, tumors, and immune - related diseases. Its business covers the entire chain of drug R & D and industrialization services, including target design, target validation, compound preparation, drug - likeness evaluation, efficacy evaluation, pharmaceutical research, clinical trials, data management and statistics, patent design, global registration and application, CDMO/CMO, etc.
Full description
The company is a comprehensive pharmaceutical R & D enterprise with technology development at its core, integrating innovation, full - value chain, platform - based, and co - inclusive attributes. It mainly provides the following services to various pharmaceutical companies and pharmaceutical R & D investment enterprises: (1) Entrusted pharmaceutical technology R & D services (CRO business); (2) R & D technology achievement transformation services; (3) Customized R & D and production services (CDMO). With a profound understanding of the industry, strong R & D capabilities, rich project development experience, and a sound quality management system, the company has provided more than 800 pharmaceutical research, clinical trial, or integrated R & D services to over 600 domestic clients.